Given the obtained data from the flow cytometry, it can be concluded that platelets express higher CD62P levels in patients with type 2 diabetes mellitus, and are pre-active at the baseline stage without the hexogen agonist treatment since the beginning as this state of platelets is related to the existing metabolic environment in patient with type 2 diabetes mellitus. Here, SELP is linked to type 2 diabetes mellitus.